The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Apr 2020 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection[1]
1	Abemaciclib	Verzenio	Malignant disease and immunosuppression	Approved	
2	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Approved	
3	Belimumab	Benlysta	Musculoskeletal and joint disease	Approved	
4	Brexipiprazole	Rexulti	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
5	Carfilzomib	Kyprolis	Malignant disease and immunosuppression	Approved	
6	Daratumumab	Darzalex	Malignant disease and immunosuppression	Approve in principle	
7	Ceftazidime / avibactam	Zavicefta	Infections	Approved	
8	Enzalutamide	Xtandi	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patient population
9	Inotuzumab ozogamicin	Besponsa	Malignant disease and immunosuppression	Approved	
10	Insulin degludec / liraglutide	Xultophy FlexTouch	Endocrine system	Approved	
11	Ixekizumab	Taltz	Musculoskeletal and joint disease	Rejected	Alternative(s) available in HADF with comparable benefits
12	Osimertinib	Tagrisso	Malignant disease and immunosuppression	Approved	
13	Rituximab	Rixathon	Malignant disease and immunosuppression	Approved	
14	Rituximab	Truxima	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
15	Rivaroxaban	Xarelto	Cardiovascular system	Pending	Pending further information
16	Sofosbuvir / velpatasvir / voxilaprevir	Vosevi	Infections	Approved	

[1] The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.